Tag: Bria-OTS™
October 16, 2019
BriaCell Announces Closing of Non-Brokered Private Placement of $568,444
BriaCell Therapeutics Corp. announces that it has closed its previously-announced non-brokered private placement. October 7, 2019
BriaCell Doses First Patient in Phase I/IIa Study Evaluating Bria-IMT™ in Combination with INCMGA00012 and Epacadostat in Patients with Advanced Breast Cancer
BriaCell Therapeutics Corp. today announced that it has initiated dosing in a Phase I/IIa clinical study of its lead product... October 2, 2019
BriaCell Therapeutics Corp. to Clarify Record Date
BriaCell Therapeutics Corp. announced on August 23, 2019 that it will hold a special meeting of shareholders on October 22,... October 1, 2019
Note from Chairman of BriaCell Therapeutics – October is Breast Cancer Awareness Month
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer.
September 25, 2019
BriaCell Appoints Immunology Expert, Dr. Cara L. Haymaker, to Scientific Advisory Board; BriaCell CEO to Lead Special ‘Targeted Immunotherapy’ Issue in Prestigious Journals
BriaCell Therapeutics announced the addition of immunology expert, Cara L. Haymaker, Ph.D., to its Scientific Advisory Board, effective immediately. September 20, 2019
BriaCell Announces Private Placement of up to $600,000
BriaCell is pleased to announce a non-brokered private placement of up to approximately 8,571,428 common shares in the capital of... September 19, 2019